Hansa Biopharma submits FDA application for kidney transplant desensitization treatment

If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant

Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027

Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia

Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US

Lupin receives USFDA approval for Bumetanide Injection

Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.

Novartis and Versant to form biotech venture Borealis Biosciences

Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company

Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24

Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line